Task: Question Answering
Input (English): Question: Regarding the designs of clinical trials to demonstrate efficacy of antidepressants, which of the following is FALSE? 
 Options:  <1> The inclusion in the design of clinical trials of secondary safety variables is important in order to establish the therapeutic location of the drugs studied. <2> In studies of depression it is not considered ethical to use a control group with placebo. <3> The efficacy of antidepressants is measured by the proportion of subjects with a predetermined percentage reduction in specific depression scales, such as Hamilton's or Beck's. <4> Due to the great variability of the response between one study and another, comparisons between active drugs with a noninferiority design do not allow to conclude efficacy in a robust way. <5> Although clinical improvement can be seen in one or two weeks, it usually takes 4 weeks of follow-up in clinical trials to establish significant differences.
Output (English): 2